Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens.

Journal of hepatology - 1 Sept 2016

Maasoumy Benjamin, Vermehren Johannes, Welker Martin-Walter, Bremer Birgit, Perner Dany, Höner Zu Siederdissen Christoph, Deterding Katja, Lehmann Patrick, Cloherty Gavin, Reinhardt Birgit, Pawlotsky Jean-Michel, Manns Michael P, Zeuzem Stefan, Cornberg Markus, Wedemeyer Heiner, Sarrazin Christoph

Abstract excerpt

BACKGROUND & AIMS: The European Association for the Study of the Liver (EASL) guidelines recommend HCV RNA measurements at specific time points during sofosbuvir(SOF)-therapy. However, it remains unclear, how these results should be interpreted. We aimed to analyze whether on-treatment HCV RNA levels predict relapse comparing the CobasAmpliPrep/CobasTaqMan v2.0 (CAP/CTM) and Abbott RealTime HCV (ART) assays....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C

Share to RNA Viruses

Share to Simeprevir

Share to Sofosbuvir

Source

Identifiers

PMID: 27085252
DOI: 10.1016/j.jhep.2016.04.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens.PMID 27085252Read ↗

Comparison of the Abbott RealTime HCV and Roche COBAS Ampliprep/COBAS TaqMan HCV assays for the monitoring of sofosbuvir-based therapy.Semantic proximity Read ↗

Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection.Semantic proximity Read ↗

Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy.Semantic proximity Read ↗

Monitoring virological responses to interferon-ribavirin and interferon monotherapy of chronic hepatitis C re-treated due to relapse or non-response.Semantic proximity Read ↗

Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients.Semantic proximity Read ↗

Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection.Semantic proximity Read ↗

Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.Semantic proximity Read ↗

Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.Semantic proximity Read ↗

Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.Semantic proximity Read ↗

Hepatitis C virus genotype 5: prospective evaluation of peginterferon/ribavirin treatment efficacy and predictive value of on-treatment virological responses for sustained virological response.Semantic proximity Read ↗

Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.Semantic proximity Read ↗

Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.